文献速递分子诊断质量管理与危急值

依据IFCC WG-LEPS建立分子诊断质量指标的初步研究:中国初步发现

A pilot study for establishing quality indicators in molecular diagnostics according to the IFCC WG-LEPS initiative: preliminary findings in China.
PubMed 文献 · Clin Chem Lab Med · 2019-01-01

该研究基于IFCC WG-LEPS通用质量指标,建立分子诊断专用质量指标,并对中国46家独立商业实验室进行问卷调查和现场检查。46家中44家(95.7%)开展分子诊断,共建立13项专用质量指标(6项优先级1,7项优先级3),3家志愿实验室数据初步验证显示新指标在错误识别和风险降低方面优势突出。

要点

  • 基于IFCC WG-LEPS通用指标建立13项分子诊断专用质量指标。
  • 46家中国独立商业实验室中44家(95.7%)开展分子诊断。
  • 3家志愿实验室初步验证显示新指标利于错误识别与风险降低。

核心结论

  • 新型分子诊断专用质量指标是监测和改进全检测过程的有力工具,可有效促进患者安全。

研究设计与样本

  • 基于IFCC WG-LEPS通用质量指标,建立分子诊断专用质量指标。
  • 对中国46家独立商业实验室进行问卷调查和现场检查。
  • 收集3家志愿实验室的专用质量指标结果以验证有效性。

主要发现

  • 46家参与实验室中44家(95.7%)开展分子诊断。
  • 共建立13项专用质量指标,其中6项为优先级1,7项为优先级3。
  • 3家志愿实验室数据预评估发现新分类的专用质量指标在错误识别和风险降低方面优势突出。

关键数值与推荐

  • 共建立13项分子诊断专用质量指标:6项优先级1,7项优先级3。
  • 46家实验室中44家(95.7%)开展分子诊断。

临床怎么用

  • 可将所建立的分子诊断专用质量指标用于监测和改进分子诊断全检测过程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background Quality indicators (QIs) are crucial tools in measuring the quality of laboratory services. Based on the general QIs of the Working Group "Laboratory Errors and Patient Safety (WG-LEPS)" of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), specific QIs have been established in order to monitor and improve the quality of molecular diagnostics, and to assess the detection level of associated disease. Methods A survey was conducted on 46 independent commercial laboratories in China, investigated using questionnaires and on-site inspections. Specific QIs established were mainly based on the specific laboratory work-flow for molecular diagnoses. The specific QI results from three volunteer laboratories were collected and used to validate their effectiveness. Results Of the 46 laboratories participating in the study, 44 (95.7%), conducted molecular diagnostics. Of 13 specific established QIs, six were priority level 1, and seven, priority level 3. At pre-evaluation of data from the three volunteering laboratories, it was found that the newly classified specific QIs had outstanding advantages in error identification and risk reduction. Conclusions Novel specific QIs, a promising tool for monitoring and improving upon the total testing process in molecular diagnostics, can effectively contribute to ensuring patient safety.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Zhou R, Wei Y, Sciacovelli L, et al. A pilot study for establishing quality indicators in molecular diagnostics according to the IFCC WG-LEPS initiative: preliminary findings in China. Clin Chem Lab Med. 2019. PMID: 30838838. doi:10.1515/cclm-2018-0966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。